The FDA’s plan to fast-track approvals for nicotine pouches is running into serious trouble, and for the industry it is a warning signal that cannot be dismissed as routine bureaucratic delay.
A Reuters investigation published on April 1 revealed that while the agency did manage to authorise six products under Altria’s on! brand through its pilot fast-track programme, applications from Philip Morris International, British American Tobacco, and Turning Point Brands remain stuck in a holding pattern. Three sources familiar with the FDA’s internal process told Reuters the science was simply not as clear-cut as reviewers had hoped — and that concerns around youth exposure and the creation of new nicotine users among non-smokers were weighing heavily on the decision.
The market reacted sharply. PMI shares fell more than seven percent on the day of the report before recovering some ground, BAT shares dropped around one and a half percent, and Turning Point Brands took the hardest hit, falling over seventeen percent. Jefferies analyst Andrei Andon-Ionita noted that BAT and PMI shares now effectively trade on pouches, which had previously been considered less complicated from a regulatory standpoint. 2Firsts That assumption now looks premature.
What the FDA Is Actually Weighing
The core tension inside the agency is one that the pouch industry has always known it would eventually face at scale. When granting licences, the FDA weighs whether a product can help smokers switch to a less harmful form of nicotine use while not driving risks too high for non-tobacco users and children. Jefferson City News Tribune For established smokers making a full switch, the calculus is relatively straightforward — pouches are widely accepted as significantly less harmful than combustible cigarettes. The harder question is what happens when a product reaches a large population that never smoked at all.
One of the sources told Reuters that the remaining applications were more complicated than expected and described them as “in a holding pattern,” with a lot of concerns around risks to youth and children. Another source said there had already been a sizeable uptick in pouch use among young adults, and that it was “not as clear” that the benefits of pending products outweighed the risks. Jefferson City News Tribune That source added bluntly: “I wouldn’t count on a slam dunk of authorisations for all of those brands.”
While FDA data shows pouch use among middle- and high-school students remains relatively low, it has been rising, prompting heightened scrutiny. Tobacco Reporter – Anti-tobacco groups including the Campaign for Tobacco-Free Kids have argued that the category’s rapid growth combined with increasingly liberal marketing strategies creates exactly the conditions for a new generation of nicotine-dependent users — an outcome the FDA is legally required to guard against.
The Stakes for PMI and BAT
For Philip Morris International, the delay is particularly damaging. PMI alone sold 794 million cans of its current version of Zyn in the United States in 2025, more than double its 2023 sales Jefferson City News Tribune — but those figures reflect an older authorised product while newer, improved versions remain in regulatory limbo. Jefferies’ Andon-Ionita said the delay is worse news for PMI specifically because Zyn has been registering significant market share losses while its newer applications await licences. Jefferson City News Tribune Competitors with authorised products are gaining ground in a window that PMI cannot yet fully compete in.
BAT, meanwhile, has stated publicly that its applications for the Velo brand warrant authorisation based on robust scientific support and that it continues to engage constructively with the agency. PMI declined to address the delay directly. Turning Point Brands, which has two pouch brands under the pilot, declined to comment entirely.
Reading the Regulatory Room
What this episode reveals is that the FDA’s fast-track programme was never the straightforward approval pipeline that markets appeared to have priced in. The agency is not simply processing paperwork — it is making genuine public health judgements that require it to weigh switching benefits for existing smokers against the risk of expanding nicotine dependence across the broader population.
The FDA’s own public position is carefully balanced. It acknowledges that pouches are generally less harmful than cigarettes and that complete switching can meaningfully reduce health risks for smokers. But it is equally firm that nicotine products are highly addictive, carry real risks even for adults, and can harm developing brains. That position leaves room for authorisation — but not automatically, and not quickly.
For an industry that has grown used to treating pouch regulation as the least complicated part of the nicotine landscape, the FDA’s caution is a recalibration. The science is not settled enough for speed, the youth data is moving in the wrong direction, and reviewers are clearly not prepared to issue blanket approvals across a category simply because one brand set a precedent. The fast-track was always a conditional offer. The industry is now finding out what the conditions actually are.
